^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH1 mutation

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
    Entrez ID:
    3417
    Related biomarkers:
    Expression
    Mutation
    Others
    Related tests:
    Apply
    Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax (NCT07471841)
    Phase 2
    Timothy Pardee
    Not yet recruiting
    Last update posted :
    03/13/2026
    Initiation :
    05/01/2026
    Primary completion :
    06/01/2028
    Completion :
    06/01/2029
    IDH1
    |
    IDH1 mutation
    |
    Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)
    Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation (NCT07130695)
    Phase 1
    Virginia Commonwealth University
    Not yet recruiting
    Last update posted :
    08/19/2025
    Initiation :
    10/31/2025
    Primary completion :
    10/31/2027
    Completion :
    10/31/2029
    IDH1
    |
    IDH1 mutation
    |
    Rezlidhia (olutasidenib)
    Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (EVOLVE 1) (NCT07075016)
    Phase 3
    Stichting Hemato-Oncologie voor Volwassenen Ned...
    Not yet recruiting
    Last update posted :
    07/20/2025
    Initiation :
    07/01/2025
    Primary completion :
    12/01/2028
    Completion :
    03/01/2029
    IDH1
    |
    IDH1 mutation
    |
    Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
    Study of Olutasidenib and Temozolomide in HGG (NCT06161974)
    Phase 2
    Rigel Pharmaceuticals
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2025
    Primary completion :
    06/01/2029
    Completion :
    06/01/2035
    IDH1
    |
    IDH1 mutation
    |
    temozolomide • Rezlidhia (olutasidenib)
    IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up (NCT04242849)
    Phase N/A
    Josep Carreras Leukaemia Research Institute
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    05/23/2016
    Primary completion :
    12/27/2019
    Completion :
    01/16/2020
    IDH1 • IDH2
    |
    IDH1 mutation • IDH2 mutation
    A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) (NCT05099003)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/18/2025
    Initiation :
    05/31/2022
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    BRAF • IDH1
    |
    BRAF mutation • BRAF V600 • IDH1 mutation
    |
    Xpovio (selinexor)
    All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma (NCT05345002)
    Phase 2
    Stephen Bagley, MD, MSCE
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    11/16/2022
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    IDH1 • IDH2 • MGMT
    |
    IDH1 mutation • IDH2 mutation
    |
    Zynyz (retifanlimab-dlwr)
    A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (NCT04576117)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/16/2021
    Primary completion :
    12/30/2026
    Completion :
    12/30/2026
    BRAF • IDH1 • NF1
    |
    BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E
    |
    Koselugo (selumetinib) • vinblastine
    Seizure Treatment in Glioma (STING) (NCT03048084)
    Phase 4
    Leiden University Medical Center
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/01/2018
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    IDH1
    |
    IDH1 mutation • IDH wild-type
    Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors (NCT02746081)
    Phase 1
    Bayer
    Completed
    Last update posted :
    12/18/2024
    Initiation :
    05/26/2016
    Primary completion :
    11/08/2018
    Completion :
    12/03/2024
    IDH1
    |
    IDH1 mutation • IDH1 R132
    |
    BAY1436032
    A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML) (NCT05756777)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    11/12/2024
    Initiation :
    06/26/2023
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    FLT3 • IDH1 • IDH2
    |
    IDH1 mutation • IDH2 mutation • FLT3 mutation
    |
    Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)
    Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma (NCI-2018-00876) (NCT03528642)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/01/2019
    Primary completion :
    12/05/2024
    Completion :
    12/05/2024
    IDH1 • IDH2
    |
    IDH1 mutation • IDH2 mutation
    |
    temozolomide • telaglenastat (CB-839)